ND Biosciences’ publishes a new paper in collaboration with the EPFL and ADX NeuroScience describing thorough characterization of
Developing
Next-Generation Therapeutics for Neurodegenerative diseases
Play Video
About us
About ND Biosciences
ND Biosciences is a spinoff from the Swiss Federal Institute of Technology in Lausanne (EPFL), that was founded to develop next-generation therapeutics for neurodegenerative diseases (NDs), such as Parkinson’s and Alzheimer’s Disease.
ND Biosciences’s therapeutic development programs are enabled by an integrated suite of novel, validated and patented drug-discovery platforms that have been developed over the past 15 years at the EPFL, and that allow for the first time to address the limitations of previously-applied technologies, and that accurately reproduce:
1) The diversity, as well as the structural and biochemical properties of pathogenic protein aggregates as observed in patient brains, thereby enabling more accurate antigen generation for drug development
2) The different stages of protein aggregation in a suite of cellular models of disease, including the only available models reproducing early and terminal aggregation stages leading to neurodegeneration, thereby enabling assessment of efficacy and identification of next-generation hits using translationally-relevant models
our science
our Publications
The technologies, innovative tools and discovery platforms deployed by ND Biosciences are based on more than 15 years of research that was carried out at the EPFL, and are well-documented in many high impact peer-reviewed publications.
Latest News
ND Biosciences awarded a grant from The Michael J. Fox Foundation to accelerate the development of its assays
ND-BioSciences Announces partnership with The Michael J. Fox Foundation for parkinson’s research to make available unique synuclein proteoforms
ND BioSciences, a Swiss-based biotechnology company that was
ND BioSciences, the Swiss biotech co-founded by Prof. Hilal Lashuel, the director of the laboratory of molecular and chemical biology
La start-up qui veut combattre les maladies neurodégénératives par des traitements novateurs
The biotech start-up based at Biopôle is developing innovative technologies for early diagnostics and therapies
The development of disease models that recapitulate the key pathological and clinical features of neurodegenerative diseases
ND BioSciences, the Swiss biotech co-founded by Prof. Hilal Lashuel, the director of the laboratory of molecular and chemical biology
ND BioSciences, a Swiss-based biotechnology company that was
Supported by
